Expanding Offerings to Clinical Dx Developers, BioreclamationIVT Acquires Asterand Bioscience

August 10, 2017
Expanding Offerings to Clinical Dx Developers, BioreclamationIVT Acquires Asterand Bioscience
BioreclamationIVT said today it has acquired Asterand Bioscience™ for an undisclosed price, in a deal designed to expand the buyer’s scientific service offerings for diagnostics as well as drug developers by supporting clinical diagnostic assay development and testing. [Source: © rare/Fotolia]

BioreclamationIVT said today it has acquired Asterand Bioscience™ for an undisclosed price, in a deal designed to expand the buyer’s scientific service offerings for diagnostics as well as drug developers.

Based in Detroit, MI and Royston, U.K., Asterand Bioscience is a global provider of high-quality, well-characterized human tissue and research solutions focused on oncology.

To that end, Asterand Bioscience also supports clinical diagnostic assay development and testing, specifically through validation of immunohistochemistry (IHC) assays. The company uses what it terms a rigorous but highly efficient experimental design as well as multiple complementary technologies, including digital pathology and quantitative image analysis.

In one case study cited by the company on its website, it performed a series of experiments to address specificity, linearity, range, accuracy, precision, and robustness of an undisclosed diagnostics developer’s IHC assay for c-Met (also known as MET, or hepatocyte growth factor receptor) in human tissues.

Asterand Bioscience was created in 2006 through the merger of Asterand, a human tissue biobank founded six years earlier, and Pharmagene a human tissue-based drug discovery company established in 1996.

Headquartered in Westbury, NY, BiofreclamationIVT specializes in control and disease-state matrices manufactured from human and animal biological specimens, and has recently expanded its offering to include cell processing and phenotypic screening services. The company aims to support precision medicine research by coupling clinical information with numerous disease-state fluids and tissues.

In addition to broadening its services to diagnostics and drug developers, BioreclamationIVT said, its acquisition of Asterand Bioscience was also intended to expand its disease-state biospecimen capabilities, particularly in cancer.

“After combining Asterand Bioscience's first-rate oncology tissue sourcing network with our existing strength in procuring disease-state tissue and clinical biofluids, BioreclamationIVT will become the market leader in disease-state biospecimens and a top resource for researchers focused on precision medicine,” BioreclamationIVT CEO Jeff Gatz said in a statement.

“The addition of Asterand Bioscience's tissue services and PhaseZERO research services groups will allow the combined company to offer a full research workflow solution, ranging from specimen sourcing through experimental design to data collection,” Gatz said.

He added that BioreclamationIVT's new offerings will include target and biomarker validation using histology and molecular techniques, as well as compound evaluation using cell-based model systems.

“The acquisition of Asterand Bioscience is an important component of our strategy to provide biopharmaceutical researchers with the highest quality, well-annotated biospecimens and a full suite of scientific services,” added BioreclamationIVT Chairman David Spaight.

The acquisition is BioreclamationIVT’s second this year. On March 9, the company acquired TransCell Science, a privately-held contract research organization (CRO) specializing in the use of primary cells for phenotypic screening assays, for an undisclosed sum.

×

Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.